DoP to select financial partner for pharma tech upgrade scheme
The Department of Pharmaceuticals (DoP) will soon initiate the process to select a financial institution for implementing the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) for small and medium enterprises.
Expression of interest to select the public sector financial institution will be called shortly, Joint Secretary, DoP, Mr. Navadeep Rinwa said at a Pharmaceuticals Export Promotion Council of India (Pharmexcil) event in Hyderabad recently.
PTUAS seeks to facilitate the enterprises upgrade plant and machinery to World Health Organisation-Good Manufacturing Practices (WHO-GMP) standards, thus enabling them to compete in global markets. At the heart is an interest subvention that will be available to small and medium scale pharma units having GMP compliant manufacturing facilities both for bulk drugs and pharmaceutical formulations. The scheme has got a budgetary allocation of Rs. 144-crore for two years (2018-2020), Mr. Rinwa said presenting the export performance awards instituted by Pharmexcil. Around 250 pharma SMEs are likely to benefit from the scheme. The Department, a part of Union Ministry of Chemicals and Fertilisers, has proposed interest subvention up to 6% per annum for a period of three years. The maximum loan eligible to the SMEs for upgradation will be Rs. 4-crore.
Looking for chemical products? Let suppliers reach out to you!
2026-06-27
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
India Raises Cancer Drug Price Caps by 50%
Recommend Reading
-
Reducing to Refocus: Novo Nordisk’s 9,000-Job Cut and the Strategic Realignment in Pharma
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
Premium Global Chemical Sourcing Requests (22-24Jun, 2026)
-
BASF Sells Oil & Gas Unit, Shifts Strategy with Major Investments
-
EU and India Advance Anti-Dumping Actions on Chemical Imports
-
Ethyl Acetate Prices Weakly Declining
-
Asahi Kasei to Double Production of Semiconductor Coating Material